Markus Puhlmann
Chief Tech/Sci/R&D Officer chez PERSPECTIVE THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Markus Puhlmann is currently the Chief Medical Officer at Perspective Therapeutics, Inc. Prior to his current position, he served as the Head-Global Clinical Development at Seagen Inc. from 2019 to 2022.
Before that, he worked as a Principal at Merck & Co., Inc. from 2015 to 2019.
Dr. Puhlmann holds a doctorate degree from Ludwig-Maximilians-Universität München and an MBA from McDonough School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/04/2024 | 1 375 425 ( 0,23% ) | 2 M $ | 31/03/2024 |
Postes actifs de Markus Puhlmann
| Sociétés | Poste | Début |
|---|---|---|
| PERSPECTIVE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Markus Puhlmann
| Sociétés | Poste | Fin |
|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | 01/01/2022 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2019 |
Formation de Markus Puhlmann
| Ludwig-Maximilians-Universität München | Doctorate Degree |
| McDonough School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
| Perspective Therapeutics, Inc. |
